News

PharmExec11h
Regeneron’s Semaglutide Plus Trevogrumab Combo Demonstrates Superior Fat Loss with Reduced Muscle Wasting in Obesity Trial
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...
PharmExec11h
Bridging Vision and Value: How Target Product Profiles and Value Evidence Archetypes Must Align for Market Access Success
In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...
PharmExec10h
Teva Unveils Positive Data for Uzedy, TEV-'749 in Schizophrenia
New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong ...
PharmExec18h
Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them
Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.